Medibank Private Ltd (ASX: MPL) shares have taken a hit in trading on Wednesday after the company announced the Australian Information Commissioner (OAIC) has commenced civil penalty proceedings against it in Federal Court.

The proceedings are in relation to the 2022 “cybercrime event”, the company says, and relate to the Commissioner’s own investigation into the event.

Medibank shares are currently trading at $3.69 apiece, down nearly 2%. Let’s take a look at what this means for the insurer.

Medibank shares hit over huge potential fines

The 2022 cyber attack on Medibank and its subsidiary AHM resulted in the exposure of sensitive customer data.

Hackers released information on the dark web, including details about names, addresses, dates of birth, phone numbers, and email addresses.

Other compromised data included Medicare numbers and, in some cases, passport numbers for international students. Medibank, following federal government advice, chose not to pay the ransom demanded by the hackers.

Maurice Blackburn Lawyers lodged a representiative complaint against Medibank, which the OAIC accepted on March 30, 2023.

In its latest submission, the OAIC alleges that Medibank “seriously interfered” with the privacy of 9.7 million Australians by “failing to take reasonable steps to protect their private information”, according to reporting by The Australian.

The OAIC is seeking penalties for each of the 9.7 million affected customers, with each contravention carrying a maximum fine of $2.22 million, The Australian Broadcasting Corporation reports.

Tallied up, this totals a staggering maximum amount of $21.5 trillion, the ABC says. However, the actual fines will be determined by the Federal Court. It is unsure how the Court will decide proceedings if ruling in favour of the Commonwealth.

Implications for Medibank shares

In today’s announcement, the ASX healthcare share stated its intent to defend the OAIC’s claims. Still, the breach has placed Medibank under scrutiny. If unsuccessful in its defence, who knows what the financial and reputational outcome of this will be.

Whilst there are no specific fine amounts listed, a maximum of $21.5 trillion is a staggering amount, more than the entire Australian GDP of US$1.7 trillion in 2023.

Medibank’s revenues were up 1.3% to $3.65 billion in H1 FY 2024. The company reported a net profit after tax (NPAT) of $233.3 million, up 6% year over year.

This was after “cybercrime costs” of $17.6 million for the period, adding to the $26.2 million the prior corresponding period.

What does this mean for investors? Well, given it is still early days, we are yet to find out. The market has yet to fully digest the news as well. Safe to say however – this is one to keep a close eye on.

Conclusion

Medibank investors have taken the news reasonably well today. The Medibank share price is down around 2% at the time of writing. In the last 12 months, the stock is up around 4%. It has climbed 4% this year to date as well.

While the exact financial impact remains uncertain, investors would be wise to stay informed about the proceedings and their potential implications for Medibank’s future performance.

The post Medibank shares dip as huge potential fines loom from 2022 data breach appeared first on The Motley Fool Australia.

More reading

• What is Goldman Sachs saying about Medibank shares in June?
• Overinvested in CBA shares? Here are two alternative ASX dividend stocks
• Here’s how I’d target a $2,000 second income by investing $35 a week
• Here are 3 reliable ASX shares I’d buy instead of the big four banks right now
• With $1,000 to invest, should I buy ASX growth stocks or income shares?

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Many of Australia’s top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week.

Three ASX shares that brokers have named as buys this week are listed below. Here’s why their analysts are feeling bullish on them right now:

Evolution Mining Ltd (ASX: EVN)

According to a note out of UBS, its analysts have retained their buy rating on this gold miner’s shares with an improved price target of $4.60. The broker feels that gold is going through a structural shift that could drive its price to A$4,000 per ounce. In light of this, the broker believes that previously flagged risks around FY 2025 guidance and medium-term cost profiles are now insignificant. Overall, it thinks that the sector is looking undervalued based on its updated gold price forecasts. The Evolution Mining share price is trading at $3.83 today.

Lovisa Holdings Ltd (ASX: LOV)

A note out of Bell Potter reveals that its analysts have retained their buy rating and $36.00 price target on this fashion jewellery retailer’s shares. This follows news that its CEO, Victor Herrero, will be leaving the company next year. Bell Potter notes that he will be replaced by John Cheston, who is the current CEO of Smiggle. While the broker sees leadership transition risk, it believes the CEO appointment aligns well to drive the next leg of growth and lift the penetration of a global business built by Herrero. Its analysts anticipate a smooth transition over the next 12 months and expect Cheston’s background to assist continued execution in Lovisa’s ~40 markets globally. The Lovisa share price is fetching $29.56 on Wednesday.

Treasury Wine Estates Ltd (ASX: TWE)

Analysts at Goldman Sachs have reiterated their buy rating and $13.00 price target on this wine giant’s shares. This follows the release of a business update and a Treasury Americas investor presentation. The broker highlights that its business update revealed that management has reiterated its guidance for FY 2024. It was pleased with this and believes it alleviates recent concerns of a US-led downgrade. In addition, the broker notes that its investor presentation provided a Luxury Strategy deep dive that was encouraging. Goldman points out that it leans into the continued premiumisation trend in the US and provides scaled synergies of both the Treasury Wine and DAOU luxury portfolios. The Treasury Wine share price is trading at $12.12 this afternoon.

The post Top brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.

More reading

• Why Generation Development, Graincorp, Seek, and Treasury Wine shares are storming higher
• Treasury Wine share price jumps on US opportunity and FY24 guidance update
• Broker says Lovisa shares are a buy following this week’s selloff
• 5 things to watch on the ASX 200 on Wednesday
• This ASX 200 superstar is down 13% in 2 days. Time to pounce?

Motley Fool contributor James Mickleboro has positions in Lovisa and Treasury Wine Estates. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Lovisa. The Motley Fool Australia has recommended Lovisa and Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Commonwealth Bank of Australia (ASX: CBA) share price is at it again.

And by ‘it’, I mean breaking into new all-time high territory.

Shares in the S&P/ASX 200 Index (ASX: XJO) bank stock are up 0.9% in early afternoon trade on Wednesday, trading for $123.53 apiece.

If CBA stock closes in the green, as looks likely, this will mark the fourth consecutive trading day of gains for Australia’s biggest bank.

It will also mark yet another record closing high.

This flies in the face of a growing chorus of bearish analysts’ assessments.

Many analysts have recently said they believe all the big four ASX 200 bank shares are overvalued. And with a lofty price-to-earnings (P/E) ratio north of 21 times, CBA tends to catch the most flak.

But as witnessed by the new record high CBA share price today, investors don’t appear to share those concerns.

The big four bank looks to be getting some support amid expectations that the level of bad loans may remain subdued. That’s in part thanks to a range of cost-of-living relief measures contained in the federal budget, which should help stressed mortgage holders meet their payments.

Today’s tepid quarterly GDP growth figures released by the ABS at 11:30am AEST have also upped the odds of earlier interest rate cuts from the Reserve Bank of Australia.

The CBA share price is up 0.25% since the GDP data hit the wires and up 26.7% in a year.

Take that bears!

The post Unstoppable! CBA share price smashes yet another record high appeared first on The Motley Fool Australia.

More reading

• Why you should sell CBA, Westpac, and Bank of Queensland shares in June
• Are ASX 200 bank shares a good investment right now?
• How the CBA share price defied the bears to surge in May
• Here’s the average wealth of Aussies who manage their own superannuation
• Buying ASX 200 bank stocks? Here’s why they could keep outperforming

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Looking to add high-quality ASX healthcare shares to your portfolio? The Australian share market is home to some of the most disruptive, innovative health companies on the planet.

ASX healthcare shares have traded flat as a group in the last three months. The S&P/ASX 200 Health Care Index (ASX: XHJ) has moved less than 1.5% since 5 March.

However, two standouts among the crowd are ResMed Inc (ASX: RMD) and CSL Ltd (ASX: CSL). Both companies are leaders in their fields and could offer attractive opportunities for growth and income, in my view.

Why ResMed is a top ASX healthcare share

ResMed is a leading player in the sleep disorder treatment market. With the rising prevalence of obstructive sleep apnoea (OSA), experts say ResMed is well-positioned for significant growth.

According to analysts at Bell Potter, the OSA market is huge. The broker says more than a billion people globally suffer from OSA, and many more remain undiagnosed.

Bell Potter reckons this massive underpenetration presents a large growth opportunity for ResMed. The broker has given the company a buy rating with a $36.00 price target. The broker cited the sleep company’s competitive edge as a tailwind, which is boosted by the ongoing recall of competitor Philips’ respiratory devices.

My colleague James reported that Macquarie analysts are also bullish on ResMed, with an ASX healthcare share valuation of $34.85. If correct, both price targets represent an upside potential of 15% and 12%, respectively.

ECP Asset Management likes ResMed as well. In April, portfolio manager Sam Byrnes told the Australian Financial Review that he believed the company was undervalued.

The ASX healthcare share “derated due to the frenzy” surrounding GLP-1s weight loss drugs, Byrnes said. “This raised concerns about the future of ResMed’s sleep apnoea treatment”.

But, even with the market’s strength in 2024, ECP still finds ResMed’s valuation “very appealing”.

CSL remains a favourite ASX healthcare share

Biotech giant CSL has long delivered attractive capital gains and dividends for its shareholders. But it has traded flat for the last two to three years.

Despite this period of sideways movement, CSL’s future looks bright, according to leading fund managers and analysts.

ECP’s Sam Byrnes is positive about CSL’s prospects as well. He highlights the company’s volume growth and reduced cost of plasma collections as key drivers of future performance.

Byrnes – along with investment bank Macquarie – has set an eye-popping share price target of $500 over the next three years.

In the short-term, Macquarie has set a price target of $330 per share (next 12 months), driven by strong earnings growth in CSL’s Behring business. This is expected to account for around 90% of CSL’s profits over the next five years.

This, it says, can drive earnings higher and push the stock price to $500 per share. Analysts at Morgans and UBS are also optimistic, with the former adding CSL to its best ideas list and setting a price target of $315.40, indicating a potential upside of 11.17%.

Putting it all together, CSL could potentially trade back above $300 per share.

Two of the best?

Both ResMed and CSL could offer compelling opportunities for ASX investors. I think ResMed’s growth potential in the sleep disorder market and CSL’s fundamentals outlook make them two of the best ASX healthcare shares that money can buy.

It pays to remember that investing comes with a degree of risk and that past performance – or price targets – are no predictors of future performance.

The post Are these 2 ASX healthcare shares the best that money can buy? appeared first on The Motley Fool Australia.

More reading

• Could the CSL share price end 2024 above $300?
• 4 high-quality ASX 200 growth shares to buy in June
• $20,000 invested in these ASX 200 shares 10 years ago is now worth… (a lot!)
• 2 ASX healthcare shares to buy now for the AI revolution
• How much passive income would a $10,000 investment in CSL shares generate?

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) is back on form on Wednesday and pushing higher. In afternoon trade, the benchmark index is up 0.4% to 7,768.7 points.

Four ASX shares that have failed to follow the market higher today are listed below. Here’s why they are falling:

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down a further 5% to 23.25 cents. Investors have been hitting the sell button this week after competition in the artificial intelligence chip market intensified significantly with both AMD and Nvidia announcing their latest releases. Given how much these companies (and others) are pouring into their research and development, some investors may now be thinking that Brainchip doesn’t have a hope in competing with these giants. Brainchip shares have lost more than 50% of their value since late February.

Immutep Ltd (ASX: IMM)

The Immutep share price is down almost 8% to 41.5 cents. This follows the successful completion of its institutional placement and the institutional component of its entitlement offer. The biotechnology company raised gross proceeds of approximately $89.6 million at an offer price of $0.38 per new share. Management notes that the placement attracted strong demand from existing institutional shareholders and also introduced several new institutional investors to the Immutep register. Dr Russell Howard, Chairman of Immutep, said: “We’re delighted to have such strong and unwavering support from our shareholders who share our belief in efti and have continued to invest in Immutep through this financing.”

Liontown Resources Ltd (ASX: LTR)

The Liontown Resources share price is down 5% to $1.22. This is despite there being no news out of the lithium developer on Wednesday. However, it is worth noting that most ASX lithium stocks are trading lower today. This follows a reasonably poor session for their counterparts on Wall Street overnight. This latest decline means that Liontown’s shares are now down by 55% since this time last year.

Xero Ltd (ASX: XRO)

The Xero share price is down 4.5% to $125.85. This has been driven by the cloud accounting platform provider launching a new convertible notes offering. Xero was aiming to raise US$850 million (A$1.28 billion) through fixed coupon guaranteed senior unsecured convertible notes due in 2031. It eventually successfully priced US$925 million 1.625% senior unsecured convertible notes. Xero’s CFO, Kirsty Godfrey-Billy, said: “We’re pleased with the response and the very strong demand for this offer. This will provide us with flexibility as we continue to execute our strategic priorities.”

The post Why Brainchip, Immutep, Liontown, and Xero shares are tumbling today appeared first on The Motley Fool Australia.

More reading

• Xero share price on watch amid $1.3 billion convertible notes offering
• 5 things to watch on the ASX 200 on Wednesday
• Why Black Cat, Brainchip, Cooper Energy, and Lovisa shares are dropping today
• This ASX index is up 13% in 2024. Is there more up its sleeve?
• 4 high-quality ASX 200 growth shares to buy in June

Motley Fool contributor James Mickleboro has positions in Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Nvidia and Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett is widely considered a legend on Wall Street, and for good reason. The conglomerate’s portfolio has substantially outperformed the benchmark S&P 500 since Buffett became CEO in 1965. 

The graph below illustrates this point:

BRK.A Total Return Level data by YCharts

A contrarian approach to investing

Moreover, Buffett’s investing methodology runs counter to modern portfolio theory and the efficient markets hypothesis.

Modern portfolio theory advocates for diversification as a risk-management strategy. According to this theory, spreading investments across various assets reduces risk, thereby increasing the probability of generating positive annual returns.

However, Buffett’s approach is anything but diversified. Berkshire Hathaway’s portfolio is concentrated, with approximately 50 stocks in its holdings at the time of this writing.

Moreover, a select few equities such as Apple (NASDAQ: AAPL), Bank of America (NYSE: BAC), American Express (NYSE: AXP), Chevron (NYSE: CVX), Coca-Cola (NYSE: KO), and Occidental Petroleum (NYSE: OXY) account for a staggering 76.6% of the conglomerate’s stock investments.

By contrast, most of Buffett’s money manager contemporaries have typically crafted portfolios consisting of hundreds — and sometimes thousands — of equities, in line with the main tenet of modern portfolio theory.

Buffett and his team have also overcome the potentially disadvantageous effects stemming from the legal requirement to disclose their quarterly buys and sells. The efficient market hypothesis suggests that such disclosures should nullify Buffett’s edge by allowing other investors to mimic his portfolio.

Surprisingly, this constraint hasn’t significantly impacted the company’s ability to deliver excess returns relative to the broader market.

In 2024, for instance, Berkshire Hathaway’s shares have outperformed the sizzling S&P 500, and historically, the company has delivered returns in excess of the broader market by around 8 percentage points per year.

Can Berkshire Hathaway keep beating the S&P 500?

When considering the likelihood of Berkshire Hathaway’s stock outperforming the S&P 500, it’s essential to analyze the company’s principal stock holdings and key economic metrics, and then compare these with the benchmark index.

The six largest stock holdings in Berkshire’s portfolio have an average forward price-to-earnings (P/E) ratio of 18.3 and anticipated earnings growth of 12.4% by 2025 (see table below).

Data source: Yahoo! Finance.

In contrast, the S&P 500 index is trading at a higher forward P/E ratio of 21.1, with an expected average earnings growth rate of 14.2% for the same period, according to FactSet analysts.

Although Berkshire Hathaway’s core stock holdings are relatively more affordable, they are projected to have a marginally lower earnings growth rate.

Turning to Berkshire Hathaway stock itself, the company’s shares are trading at a forward P/E ratio of 18.8 and are predicted to have earnings growth of 2.4% for the following year.

This significantly lower earnings growth rate suggests that Berkshire Hathaway’s stock may not be well positioned to outperform the S&P 500 in the short term.

Cut from a different cloth

Still, a deeper analysis is ultimately required to answer the original question, because Berkshire Hathaway isn’t a typical stock.

Buffett and his team have amassed a diverse portfolio of assets, including stocks, bonds, businesses, and a substantial cash reserve. This multifaceted approach sets it apart from most other companies.

What does this all mean in practical terms? Due to its diverse asset portfolio, Wall Street regards Berkshire Hathaway as an exceptional hedge against broad market downturns.

Unlike the S&P 500, which lacks built-in downside protection, Berkshire Hathaway’s strategic composition provides a safety net during turbulent times.

Uncertainty looms

Now, let’s explore why this distinction matters. The S&P 500’s recent bull market surge owes much to the enthusiasm surrounding artificial intelligence (AI). Notably, Nvidia (NASDAQ: NVDA) — the chipmaker at the forefront of the AI revolution — holds the second-largest weight within the S&P 500. Consistently surpassing Wall Street’s earnings expectations, Nvidia has become a linchpin for the index’s performance lately.

However, here’s the crux: If Nvidia encounters any obstacles, ripple effects could reverberate throughout the entire U.S. stock market. In contrast, Berkshire Hathaway maintains limited exposure to this AI-centric theme. Its substantial focus lies in sectors such as finance, energy, and consumer goods, shielding it to a degree from the hype surrounding AI.

Although Apple is Berkshire Hathaway’s largest holding by a country mile, the tech giant doesn’t rely on AI to fuel sales. Instead, Apple leverages its loyal customer base to drive sales of its iconic iPhone. Berkshire Hathaway, in turn, isn’t overly reliant on AI to drive its share-price performance, counter to the broader market.

All roads lead to Nvidia

Berkshire Hathaway’s ability to outperform the S&P 500 in the short term hinges on Nvidia’s trajectory. Should Nvidia continue to exceed Wall Street’s estimates by a wide margin, Buffett’s conglomerate is unlikely to best the S&P 500 over the next 18 months.

However, a more profound concern looms: The S&P 500 appears markedly overvalued based on its cyclically adjusted price-to-earnings ratio. Furthermore, its bull run appears overly reliant on a single stock.

Perhaps most concerning is that Nvidia’s shares are trading at over 42 times forward earnings. This premium valuation may be warranted, but it also suggests that a fair amount of the chipmaker’s near-term upside is already accounted for, curtailing its power to drive the S&P 500 much higher.

A favorable scenario for Berkshire Hathaway

If investors balk at paying this hefty premium for Nvidia, Berkshire Hathaway should deliver superior results relative to the benchmark index over the next 18 months.

In other words, Nvidia stock may lose momentum as investors search for more attractive growth vehicles. This dynamic that favors companies like Berkshire Hathaway — namely, ones that aren’t entirely dependent on AI to create shareholder value.

Berkshire Hathaway, despite its unfavorable econometrics relative to the S&P 500, could thus deliver strong returns for shareholders over the remainder of 2024 and the whole of 2025 if this scenario plays out.

That’s a testament to Buffett’s slow-and-steady approach to value creation, which has consistently beaten the broader markets over the past seven decades and counting. 

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post Can Berkshire Hathaway stock keep outpacing the S&P 500? appeared first on The Motley Fool Australia.

More reading

• How Warren Buffett’s advice is guiding the ASX shares I’m buying in 2024
• How you could retire rich by investing like Warren Buffett with ASX shares
• Warren Buffett’s sister uses this simple method for passive income without dividends
• 1 concerning number from Warren Buffett’s annual shareholder meeting that should raise flags for investors
• The secret stock Warren Buffett just spent $10 billion on (and finding similar ASX shares)

George Budwell has positions in Apple. Bank of America is an advertising partner of The Ascent, a Motley Fool company. American Express is an advertising partner of The Ascent, a Motley Fool company. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Apple, Bank of America, Berkshire Hathaway, Chevron, and Nvidia. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Occidental Petroleum. The Motley Fool Australia has recommended Apple, Berkshire Hathaway, and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.